申请人:The Children's Medical Center Corporation
公开号:EP2143444A9
公开(公告)日:2013-02-27
The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
本发明包括一组能有效抑制血管生成的化合物。更具体地说,沙利度胺和各种相关化合物,如沙利度胺前体、类似物、代谢物和水解产物,已被证明可抑制血管生成和治疗血管生成导致的疾病状态。此外,抗炎药物,如类固醇和非甾体抗炎药物,可单独或与沙利度胺及相关化合物联合使用,抑制血管生成相关疾病。重要的是,这些化合物可以口服给药。